NRXBF and NRX Related Headlines
Go Back- NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
- NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
- Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
- NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
- NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
- NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
- NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
- NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
- NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
- NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
NRXBF and NRX Related Press Releases
Go Back- NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update
- NurExone Receives Notice of Patent Grant in South Korea Covering ExoPTEN Technology
- Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
- NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
- NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis
- NurExone Secures over C$3.18 Million Through Accelerated Warrant Exercises
- NurExone Accepted into ARMI’s BioFab Startup Lab Strengthening U.S Position in Regenerative Manufacturing
- NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
- NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment
- NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups
